This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT01339052
Previous Study | Return to List | Next Study

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Massachusetts General Hospital
Novartis Pharmaceuticals
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
University of California, Los Angeles
University of Utah
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier:
NCT01339052
First received: April 18, 2011
Last updated: July 13, 2017
Last verified: July 2017
April 18, 2011
July 13, 2017
September 2011
October 2016   (Final data collection date for primary outcome measure)
  • Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1] [ Time Frame: Samples were collected at baseline and at surgery (resected surgical tumor specimen) which occurred after up to 12 days of BKM120 treatment. ]
    pAKT response was determined by pathologist-performed semi-quantitative IHC scoring for pAKT using previously established methods for glioblastoma (GBM) patients. Sample staining scored for intensity on a 0-2+ scale (0 none, 1+ weak positive, 2+ strong positive). Change in pAKT IHC score was the difference in score from baseline to surgery. Participants were classified into 3 groups: a reduction of staining score of one degree or more (considered a response), an increase in score and no change in score.
  • 6-Month Progression-Free Survival (PFS6) [Cohort 2] [ Time Frame: Participants were assessed radiologically every other cycle on treatment; Relevant for this outcome is up to month 6 evaluation. ]
    PFS6 is the proportion of participants remaining alive and progression-free at 6-months from cycle 1 day 1 of BKM120 treatment. Progressive disease is defined using RANO (Response Assessment in Neuro-Oncology) criteria (Wen et al JCO 2010), which takes modified Macdonald Criteria and adds assessment of non-enhancing lesions. Per RANO, progressive disease (PD) is defined either as > 25% increase in sum of the products of perpendicular diameters of enhancing lesions on stable or increasing doses of corticosteroids, or one or more of the of the following: 1) Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids steroids not due to co-morbid events; 2) Any new lesion; 3) Clear clinical deterioration not attributable to other causes apart from the tumor; or 4) Failure to return for evaluation due to death or deteriorating condition.
  • BKM120 Brain-to-Plasma Ratio at Time of Surgery [Cohort 1] [ Time Frame: Samples were collected at surgery (surgical tumor specimen and plasma sample) which occurred after up to 12 days of BKM120 treatment. ]
    Levels of BKM120 were determined by liquid chromatography coupled with tandem mass spectrometry. BKM120 tumor-to-plasma ratio at time of surgery was calculated based on these levels.
  • BKM120 Tumor Tissue Concentration at Time of Surgery [Cohort 1] [ Time Frame: Samples were collected at surgery (resected surgical tumor specimen) which occurred after up to 12 days of BKM120 treatment. ]
    Levels of BKM120 were determined by liquid chromatography coupled with tandem mass spectrometry.
  • BKM120 Plasma Concentration at Time of Surgery [Cohort 1] [ Time Frame: Samples were collected at surgery which occurred after up to 12 days of BKM120 treatment. ]
    Levels of BKM120 were determined by liquid chromatography coupled with tandem mass spectrometry.
  • Cohort I: To evaluate PI3K pathway modulation of BKM120 in tumor tissue. [ Time Frame: 1 year ]
    PI3-Kinase pathway modulation will be measured using immunohistochemistry analyses of unstained tumor tissue to identify PI3-Kinase mutations including PIK3CA mutations, PTEN mutations, and PTEN deletion by immunohistochemistry. Expression of pAKT will also be analyzed using immunohistochemistry.
  • Cohort II: To investigate the treatment efficacy of BKM120 in participants with recurrent GBM as measured by 6-month progression-free survival [ Time Frame: 1 year ]
    Treatment efficacy will be based upon 6-month progression-free survival status. Progressive disease is defined using RANO (Response Assessment in Neuro-Oncology criteria.
  • Cohort I: To evaluate BKM120 concentration in tumor tissue, plasma, and cerebrospinal fluid. [ Time Frame: 1 year ]
    Blood will be collected over various time points prior to surgery to determine individual pharmacokinetics. During surgery, tumor tissue, plasma, and cerebrospinal fluid will be collected simultaneously. Tumor and plasma concentrations of the drug will be measured by liquid chromatography with tandem mass spectrometry to derive a tumor/plasma ratio. Descriptive statistics (mean, SD, CV% or median (range)) will be performed on all plasma concentration-time data and derived PK parameters.
Complete list of historical versions of study NCT01339052 on ClinicalTrials.gov Archive Site
  • % Ki-67 Reduction Using Immunohistochemistry (IHC) [Cohort 1] [ Time Frame: Samples were collected at baseline (archival tumor specimen) and at surgery (surgical tumor specimen) which occurred after up to 12 days of BTK120 treatment. ]
    Tumor cell proliferation and tumor cell death was using immunohistochemistry for Ki-67 based on established methods. Percent reduction was based on Ki-67 levels at baseline and at surgery.
  • Radiographic Response [Cohort 2] [ Time Frame: Participants were assessed radiologically every other cycle on treatment. Cohort 2 participants were on treatment up to 9.2 months. ]
    Radiographic response was based on RANO (Response Assessment in Neuro-Oncology) criteria. Per RANO, complete response (CR): 1) Complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks, 2) No new lesions, 3) All lesions assessed using the same techniques as baseline, 4) No steroid use (or on physiologic replacement doses only), 5) Stable or improved non-enhancing (T2/FLAIR) lesions and 6) Stable or improved clinically; partial response (PR): 1) >/= 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions (sum LD) sustained for at least 4 weeks and 2) No progression; progressive disease (PD): 1) > 25% increase sum LD and/or 2) significant increase in T2/FLAIR, 3) any new lesion, 4) clear clinical deterioration; stable disease (SD): none of the above.
  • Maximum Observed Plasma Concentrations (Cmax) of BKM120 Day 1 and Day 8 [Cohort 1] [ Time Frame: On days 1 and 8 (+/- 1 day) prior to surgery, 5 blood samples were collected at the following timepoints: pre-dose, and at 0.5, 1.5, 3, and 5 hours post-dose. ]

    Plasma concentrations of BKM120 were analyzed by a validated liquid chromatography-tandem mass spectrometry assay developed by Novartis Pharma AG. Standard Pk parameters were determined using non-compartmental methods.

    NOTE: This outcome measure was previously titled: "Investigate Pharmacokinetics of BKM120 in This Population by Comparing Maximum Plasma Concentrations (Cmax) From Day 1 to Day 8"

  • Cmax Accumulation Ratio of BKM120 Day 1 and Day 8 Ratio [Cohort 1] [ Time Frame: On days 1 and 8 (+/- 1 day) prior to surgery, 5 blood samples were collected at the following timepoints: pre-dose, and at 0.5, 1.5, 3, and 5 hours post-dose. ]
    Plasma concentrations of BKM120 were analyzed by a validated liquid chromatography-tandem mass spectrometry assay developed by Novartis Pharma AG. Standard Pk parameters were determined using non-compartmental methods. The accumulation ratio is day 8/day 1.
  • Area Under the Concentration Curve From Time 0 to Last Concentration (AUC0-5h) of BKM120 Day 1 and Day 8 [Cohort 1] [ Time Frame: On days 1 and 8 (+/- 1 day) prior to surgery, 5 blood samples were collected at the following timepoints: pre-dose, and at 0.5, 1.5, 3, and 5 hours post-dose. ]

    Plasma concentrations of BKM120 were analyzed by a validated liquid chromatography-tandem mass spectrometry assay developed by Novartis Pharma AG. Standard Pk parameters were determined using non-compartmental methods.

    NOTE: This outcome measure was previously titled: "Investigate Pharmacokinetics of BKM120 in This Population by Comparing the Drug Exposure Area Under the Curve (AUC0-5h) From Day 1 to Day 8"

  • AUC0-5h Accumulation Ratio of BKM120 Day 1 and Day 8 [Cohort 1] [ Time Frame: On days 1 and 8 (+/- 1 day) prior to surgery, 5 blood samples were collected at the following timepoints: pre-dose, and at 0.5, 1.5, 3, and 5 hours post-dose. ]

    Plasma concentrations of BKM120 were analyzed by a validated liquid chromatography-tandem mass spectrometry assay developed by Novartis Pharma AG. Standard Pk parameters were determined using non-compartmental methods.

    The accumulation ratio is day 8/day 1.

  • Time to Maximum Observed Plasma Concentration (Tmax) of BKM120 Day 1 and Day 8 [Cohort 1] [ Time Frame: On days 1 and 8 (+/- 1 day) prior to surgery, 5 blood samples were collected at the following timepoints: pre-dose, and at 0.5, 1.5, 3, and 5 hours post-dose. ]
    Plasma concentrations of BKM120 were analyzed by a validated liquid chromatography-tandem mass spectrometry assay developed by Novartis Pharma AG. Standard Pk parameters were determined using non-compartmental methods.
  • Overall Survival (OS) [Cohort 2] [ Time Frame: Participants were followed long-term for survival via medical record review. Cohort 2 participants were followed for survival up to 52 months in this study cohort. ]
    Overall survival is defined as the time from date of first dose to death or date last known alive and estimated using Kaplan-Meier (KM) methods.
  • Progression-Free Survival (PFS) [Cohort 2] [ Time Frame: Participants were assessed radiologically every other cycle on treatment and off-treatment via medical record review until death. Cohort 2 participants were followed for progression-free survival up to 12 months in this study cohort. ]
    PFS is defined as the time from first dose to the earliest documentation of disease progression or death. Participants alive without evidence of PD were censored at the date of last disease assessment. Progressive disease was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010). See outcome measure #2.
  • Grade 3-5 Treatment-Related Toxicity Rate [ Time Frame: Adverse events experienced by participants are collected and reported throughout treatment with study drug (from initiation of study medication until 30 days after the last dose of BKM120), maximum timeframe was 2 years. ]
    The percentage of patients who experienced any grade 3-5 treatment-related adverse event based on CTCAEv4 as reported on case report forms.
  • Cohort I: To evaluate effects of BKM120 on tumor cell proliferation and tumor cell death [ Time Frame: 1 year ]
    Modulation in pAKT scoring as measured by reduction of staining intensity of one degree or more will be reported as consistent with a positive response to drug. In addition, participants will be independently scored as a positive response if a reduction in the percentage of pAKT positive cells within a tumor is greater than 50%, and therefore less likely due to normal geographic variation in positivity patterns. All pathway modulation scores will be correlated with effects on tumor growth by measuring Ki-67 (proliferation) and cleaved caspase 3 (CC3) (apoptosis/cell death).
  • Cohort I: To investigate the safety profile of BKM120 in participants with recurrent GBM [ Time Frame: 1 year ]
    To assess the probability of toxicity associated with the treatment, the proportion of subjects with different grades of toxicities will be analyzed in order to further expland the safety profile for BKM120.
  • Cohort I: To investigate pharmacokinetics of BKM120 in this population [ Time Frame: 1 year ]
    Pharmacokinetic parameters of BKM120 will be determined, either using a two-stage compartmental analysis or using a non-linear mixed-effect approach. Pharmacokinetic parameters that will be derived include, but are not limited to oral drug clearance (CL/F), central and peripheral volume of distribution (V1 and V2) and absorption rate constant (Ka). Descriptive statistics (mean, SD, CV% or median (range)) will be performed on all plasma concentration-time data and derived PK parameters.
  • Cohort II: To investigate the radiographic response to BKM120 [ Time Frame: 1 year ]
    Participants will be evaluated for radiographic response. Response rate will be the proportion of participants with measurable disease who experience complete or partial radiographic response determined by the RANO Criteria
  • Cohort II: To investigate median progression free survival and overall survival of participants with recurrent GBM receiving treatment with BKM120 [ Time Frame: 1 year ]
    Median time to progression (defined using RANO criteria) and duration of survival will be measured in months for all enrolled cohort II participants.
Not Provided
Not Provided
 
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway
BKM120 is a newly discovered drug that has been used in other research studies. Information from those other research studies suggests that BKM120 may help to slow or stop the growth of malignant gliomas. The purpose of this study is to see how well BKM120 works in patients with malignant gliomas. Patients on this study will be treated in two groups: patients who are going to receive surgery and those who will not receive surgery. This study is trying to determine how effective BKM120 is in stopping cancer cells from growing. For patients receiving surgery the research will also try to determine if an effective level of BKM120 can penetrate the brain before surgery.

OBJECTIVES:

Cohort 1

Primary Objectives

  • Evaluate PI3K pathway modulation due to BKM120 in tumor tissue
  • Evaluate BKM120 concentration in tumor tissue, plasma, and cerebrospinal fluid

Secondary Objectives

  • Evaluate effects of BKM120 on tumor cell proliferation and tumor cell death
  • Investigate the safety profile of BKM120 in this population
  • Investigate pharmacokinetics of BKM120 in this population

Exploratory Objectives

  • Correlate FDG-PET and FLT-PET with pharmacodynamic effects and 6-month progressive-free survival (PFS6)
  • Determine the effects of BKM120 on primary GBM cell lines derived from participants and correlate with participant benefit from BKM120 treatment

Cohort 2

Primary Objective

  • Investigate the treatment efficacy as measured by 6-month progressive-free survival (PFS6)

Secondary Objectives

  • Investigate the radiographic response, progression free survival, overall survival
  • Investigate the safety profile efficacy of BKM120 in this population

Exploratory Objectives

  • Correlate benefit from BKM120 treatment with molecular genotype of tumor (using immunohistochemistry, mutation analysis and RNA expression profiling), and whole blood proteomics
  • Correlate benefit from BKM120 treatment with circulating angiogenic biomarkers
  • Utilize advance MRI (perfusion, permeability, diffusion imaging) to determine the effects of BKM120 on tumor vasculature and to correlate with benefit from BKM120 treatment

STATISTICAL DESIGN:

Cohort 1

The primary endpoint for Cohort 1 is modulation of PI3 kinase pathway based on change in immunohistochemistry (IHC) scoring for pAKT. Modulation in scoring as measured by reduction of staining intensity score of one degree or more was reported as a positive response to drug. This portion of the trial would be considered a success if 9 or more participants of 15 participants showed a response. There was a 94% chance of this occurring if the true response rate was 75% and only a 10% chance of this occurring if the true response rate was 40%.

Cohort 2

The primary endpoint for Cohort 2 is the proportion of participants progression free at 6 months (PFS6). Historical comparison data suggest that ineffective therapies in recurrent GBM have a PFS6 rate of approximately 9-16% (Wong 1999; Lamborn 2008). This trial was sized to differentiate between a 15% versus a 32% PFS6. With a total sample size of 50 participants, this design yields at least 90% power with a one sided alpha < 0.1 to detect a true PFS6 rate of at least 32%. If the number of successes was ≥ 12, the therapy would be considered worthy of further study.

Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Glioblastoma
  • Drug: BKM120
    Other Name: Busparlisib
  • Procedure: Surgery
    Surgery
  • Experimental: Cohort 1: Surgical subjects

    Subjects scheduled for surgery

    BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery

    Surgery: Surgery

    BKM120: 100 mg once daily, orally, for 28-day cycles

    Patients continued treatment until disease progression or unacceptable toxicity.

    Interventions:
    • Drug: BKM120
    • Procedure: Surgery
  • Experimental: Cohort 2: Non-surgical subjects

    Subjects not candidates for surgery

    BKM120: 100 mg once daily, orally, for 28-day cycles

    Patients continued treatment until disease progression or unacceptable toxicity.

    Intervention: Drug: BKM120
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
65
October 2017
October 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants must be able to understand and be willing to sign a written informed consent document.
  • Subjects must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diary.
  • Participants must be at least 18 years old.
  • Participants must have a Karnofsky performance status (KPS) ≥ 60. Nature of illness and treatment history
  • Participants must have histologically confirmed glioblastoma or variants. Participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made.
  • Participants may have had treatment for no more than 1 prior relapse(NOTE: Relapse is defined as progression following initial therapy (i.e., radiation ± chemotherapy)). The intent therefore is that patients had no more than 2 prior therapies (initial and treatment for 1 relapse). If the participant had a surgical resection for relapsed disease and no antitumor therapy was instituted for up to 12 weeks, and the participant undergoes another surgical resection, this is considered as a second relapse. For participants who had prior therapy for a low-grade glioma, the surgical diagnosis of a high-grade glioma will be considered the first relapse).
  • Participants must have shown unequivocal evidence for tumor progression by MRI or CT scan.
  • For Cohort 2, CT or MRI within 14 days prior to start of study drug. MRIs should include vascular imaging when possible. For Cohort 2, corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan. If steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required. For Cohort 1 subjects, CT or MRI should be performed ideally within 14 days prior to study registration, but because the screening MRI for this subset of subjects will not be used for evaluation of response, it is acceptable for this MRI/CT to have been performed greater than 14 days prior to registration if unavoidable. Furthermore, for this same reason, fluctuation in corticosteroid dose around this MRI does not warrant repeat scan so long as there is documented unequivocal evidence of tumor progression available.
  • For Cohort 2, Immunohistochemical or genetic analysis on tumor tissue from a prior surgery must demonstrate activation of the PI3K pathway through one of the following: PIK3CA mutation of PIK3R1 mutation, PTEN negativity (<10% of tumor cells staining) oh immunohistochemistry, PTEN mutation (any), homozygous deletion of PTEN
  • Participants must have failed prior radiation therapy and must have an interval of at least 12 weeks from the completion of radiation therapy to study entry.
  • Participants must have recovered to a grade 0 or 1 from the toxic effects of prior therapy (with the exception of lymphopenia which is common after therapy with temozolomide).
  • From the projected start of scheduled study treatment, the following time periods must have elapsed: 4 weeks or 5 half-lives (whichever is shorter)from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies, or 4 weeks or 5 half-lives (whichever is shorter) from other anti-tumor therapies.
  • Participants with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of progressive disease based upon nuclear imaging, MR spectroscopy, perfusion imaging or histopathology.
  • Participants having undergone recent resection of recurrent or progressive tumor will be eligible for Cohort 2 as long as the following conditions apply: a) They have recovered from the effects of surgery; b) Residual disease following resection of recurrent tumor is not mandated for eligibility. To best assess the extent of residual disease postoperatively, an MRI or CT scan should ideally been performed no later than 96 hours following surgery or at least 28-days postoperatively, but scans performed outside of this window are considered acceptable if no alternative is available. In either case, the baseline/screening MRI must be performed within 14 days prior to registration. If the participant is taking corticosteroids, the dose must be stable or decreasing for at least 5 days prior to the scan. If steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required.
  • Participants must have sufficient tissue from prior surgery for confirmation of diagnosis and correlative studies. Submission of tissue is to occur within 30 days after registration. The following amount of tissue is required: a) 25 unstained formalin fixed paraffin embedded (FFPE) sections (standard 4-5 micrometer thickness AND b)one of the following: i) At least 200 micrograms of frozen tissue OR ii)At least 10 (preferably 20) unstained FFPE sections of 10 micrometer thickness OR iii) At least 8 tissue cores from an FFPE block (200 micrometer total thickness of tissue from a block with a total surface area of 0.5 cm2)
  • Clinical laboratory tests within 14 days prior to enrollment meeting the criteria listed in the protocol
  • Cardiovascular assessment: baseline MUGA or Echocardiogram must demonstrate LVEF ≥ 50 %
  • Electrocardiogram must demonstrate QTc interval of less than 480 msec
  • Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
  • Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective contraception (defined in protocol) during study treatment and for 16 weeks after study discontinuation.
  • Women of child-bearing potential must have a negative serum pregnancy test at screening and within 48 hours prior to dosing with the study drug.
  • Fertile males, defined as all males physiologically capable of conceiving offspring, must use condom during study treatment and for 16 weeks after study discontinuation and should not father a child in this period.
  • Female partner of male study subject should use highly effective contraception while receiving study agent and for 16 weeks after final dose of study therapy.

Cohort 1 Inclusion Criteria (In addition to the general eligibility criteria, participants in the Cohort 1 preoperative portion of the study must meet the following criteria on screening examination to be eligible):

  • A participant who is deemed by the site Investigator to be an appropriate candidate for surgical resection may be enrolled in the Cohort 1 preoperative study.
  • There must be sufficient recurrent tumor to allow at least 400mg of tissue to be collected ( 2 X 0.5 cm3) for pharmacokinetic and pharmacodynamic analysis.
  • Central Immunohistochemical analysis (by Dr. Ligon at DFCI) on tumor tissue from an earlier surgery must indicate pAKT positivity (1-2+ on a 0-2+ scale). [Cohort I patients' tissue may also demonstrate activation of the PI3K pathway via one of the criteria listed for Cohort 2 participants, but this is not mandatory.]

Exclusion Criteria:

  • Participants who have received prior treatment with a P13K inhibitor, AKT inhibitor, mTOR inhibitor (e.g. rapamycin, MK2206, perifosine etc.).
  • Participants who have received anti-angiogenic or anti-VEGF targeted agents (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL184, sunitinib etc).
  • Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participant must be off any EIAEDs for at least two weeks prior to starting study drug. A list of EIAED and other inducers of CYP3A4 is provided in Table C-3 of Appendix C of the protocol.
  • Participants taking a drug known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A (protoocol Appendix C). Participant must be off CYP3A inhibitors and inducers for at least two weeks prior to starting study drug. NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction.
  • Requirement of more than 8mg of dexamethasone daily.
  • Participants taking drugs with known risk to promote QT prolongation and Torsades de Pointes (refer to protocol).
  • Participants receiving any other investigational agents.
  • Current use of herbal preparations/medications, including but not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, ginseng. Participants should stop using these herbal medications 7 days prior to first dose of study drug.
  • Current use of warfarin sodium or any other coumadin-derivative anticoagulant. Participant must be off Coumadin-derivative anticoagulants for at least 7 days prior to starting study drug. Low molecular weight heparin is allowed.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BKM120.
  • History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, chronic liver disease (e.g., cirrhosis, hepatitis), chronic renal disease, pancreatitis, chronic pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements. Subjects must be free of any clinically relevant disease (other than glioma) that would, in the Investigator's opinion, interfere with the conduct of the study or study evaluations.
  • Individuals with a history of a different malignancy except for the following circumstances: if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • Known diagnosis of human immunodeficiency virus (HIV) infection
  • Participants with history of protocol specified mood disorders as judged by the Investigator or a psychiatrist, or as result of participant's screening mood assessment questionnaire
  • Participants with diarrhea ≥ CTCAE grade 2
  • Participant has active cardiac disease including any of the following: Angina pectoris that requires the use of anti-anginal medications; Ventricular arrhythmias except for benign premature ventricular contractions; Supraventricular and nodal arrythmias requiring a pacemaker or not controlled with medication; Conduction abnormality requiring a pacemaker; Valvular disease with document compromise in cardiac function; Symptomatic pericarditis
  • Participant has a history of cardiac dysfunction including any of the following: Myocardial infraction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF function; History of documented congestive heart failure (New York Heart Association functional classification III-IV; c)Documented cardiomyopathy; d) Congenital long QT syndrome
  • Participants with poorly controlled diabetes mellitus (glycosylated hemoglobin > 8%) or poorly controlled steroid-induced diabetes mellitus (glycosylated hemoglobin > 8%)
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or extensive small bowel resection). Participants with unresolved diarrhea will be excluded as previously indicated.
  • Participants who have undergone major systemic surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01339052
11-033
CBKM120XUS07T ( Other Identifier: Novartis )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
Patrick Y. Wen, MD
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Novartis Pharmaceuticals
  • M.D. Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • University of California, San Francisco
  • University of California, Los Angeles
  • University of Utah
Principal Investigator: Patrick Y Wen, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP